Berres Jennifer
Known title: SVP & Chief Human Res. OfficerCIK: 0001793262
Associated companies
Transaction History
| HCA | ▼ Sell | Open Market | 4,010 | $2.0M | 2/11/2026 | View on chart |
| HCA | ▼ Sell | Open Market | 4,010 | $2.1M | 2/11/2026 | View on chart |
| HCA | ▲ Buy | Grant | 7,116 | $0 | 2/10/2026 | View on chart |
| HCA | ▼ Sell | Tax Withholding | 2,515 | $1.3M | 2/10/2026 | View on chart |
| HCA | ▼ Sell | Open Market | 4,155 | $1.3M | 2/14/2025 | View on chart |
| HCA | ▼ Sell | Open Market | 5,378 | $1.7M | 2/14/2025 | View on chart |
| HCA | ▲ Buy | Grant | 1,588 | $0 | 2/13/2025 | View on chart |
| HCA | ▼ Sell | Tax Withholding | 407 | $131K | 2/13/2025 | View on chart |
| HCA | ▲ Buy | Option Exercise | 7,440 | $753K | 2/7/2025 | View on chart |
| HCA | ▲ Buy | Option Exercise | 4,340 | $604K | 2/7/2025 | View on chart |
| HCA | ▼ Sell | Tax Withholding | 6,747 | $2.2M | 2/7/2025 | View on chart |
| HCA | ▼ Sell | Tax Withholding | 3,240 | $1000K | 2/16/2024 | View on chart |
| HCA | ▲ Buy | Grant | 9,420 | $0 | 2/16/2024 | View on chart |
| HCA | ▼ Sell | Tax Withholding | 2,441 | $642K | 2/17/2023 | View on chart |
| HCA | ▲ Buy | Grant | 7,600 | $0 | 2/17/2023 | View on chart |
| HCA | ▼ Sell | Open Market | 4,000 | $1.0M | 2/7/2023 | View on chart |
| HCA | ▼ Sell | Open Market | 2,358 | $516K | 5/13/2022 | View on chart |
| HCA | ▲ Buy | Grant | 2,520 | $0 | 2/18/2022 | View on chart |
| HCA | ▲ Buy | Grant | 6,200 | $0 | 2/18/2022 | View on chart |
| HCA | ▼ Sell | Tax Withholding | 2,827 | $690K | 2/18/2022 | View on chart |
| HCA | ▲ Buy | Option Exercise | 5,130 | $357K | 11/5/2021 | View on chart |
| HCA | ▲ Buy | Option Exercise | 5,510 | $452K | 11/5/2021 | View on chart |
| HCA | ▼ Sell | Tax Withholding | 6,163 | $1.5M | 11/5/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
HCA Q2 Earnings and Analyst Optimism Amid Valuation Concerns
HCA Healthcare reported strong Q2 earnings compared to other hospital chains, prompting TD Cowen to raise its price target to $460. While some analysts note the stock could trade at a discount following a 96% run, others argue its strong outpatient partnerships and financial health make it too healthy to downgrade. The company's solid performance continues to draw attention from major market lists and value stock screens.
HCA Q2 Earnings and Analyst Optimism Amid Valuation Concerns. HCA Healthcare reported strong Q2 earnings compared to other hospital chains, prompting TD Cowen to raise its price target to $460. While some analysts note the stock could trade at a discount following a 96% run, others argue its strong outpatient partnerships and financial health make it too healthy to downgrade. The company's solid performance continues to draw attention from major market lists and value stock screens.